scholarly journals Different Somatic Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-Generation Sequencing-Based Antibody Repertoire Analysis

2017 ◽  
Vol 8 ◽  
Author(s):  
Kazutaka Kitaura ◽  
Hiroshi Yamashita ◽  
Hitomi Ayabe ◽  
Tadasu Shini ◽  
Takaji Matsutani ◽  
...  
PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0149393 ◽  
Author(s):  
Kendrick B. Turner ◽  
Jennifer Naciri ◽  
Jinny L. Liu ◽  
George P. Anderson ◽  
Ellen R. Goldman ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Crescenzio Francesco Minervini ◽  
Cosimo Cumbo ◽  
Immacolata Redavid ◽  
Maria Rosa Conserva ◽  
Paola Orsini ◽  
...  

AbstractThe evaluation of the somatic hypermutation of the clonotypic immunoglobulin heavy variable gene has become essential in the therapeutic management in chronic lymphocytic leukemia patients. European Research Initiative on Chronic Lymphocytic Leukemia promotes good practices and standardized approaches to this assay but often they are labor-intensive, technically complex, with limited in scalability. The use of next-generation sequencing in this analysis has been widely tested, showing comparable accuracy and distinct advantages. However, the adoption of the next generation sequencing requires a high sample number (run batching) to be economically convenient, which could lead to a longer turnaround time. Here we present data from nanopore sequencing for the somatic hypermutation evaluation compared to the standard method. Our results show that nanopore sequencing is suitable for immunoglobulin heavy variable gene mutational analysis in terms of sensitivity, accuracy, simplicity of analysis and is less time-consuming. Moreover, our work showed that the development of an appropriate data analysis pipeline could lower the nanopore sequencing error rate attitude.


2019 ◽  
Vol 20 (2) ◽  
pp. 417 ◽  
Author(s):  
Soohyun Kim ◽  
Hyunho Lee ◽  
Jinsung Noh ◽  
Yonghee Lee ◽  
Haejun Han ◽  
...  

: YYB-101 is a humanized rabbit anti-human hepatocyte growth factor (HGF)-neutralizing antibody currently in clinical trial. To test the effect of HGF neutralization with antibody on anti-cancer T cell immunity, we generated surrogate antibodies that are reactive to the mouse homologue of the epitope targeted by YYB-101. First, we immunized a chicken with human HGF and monitored changes in the B cell repertoire by next-generation sequencing (NGS). We then extracted the VH gene repertoire from the NGS data, clustered it into components by sequence homology, and classified the components by the change in the number of unique VH sequences and the frequencies of the VH sequences within each component following immunization. Those changes should accompany the preferential proliferation and somatic hypermutation or gene conversion of B cells encoding HGF-reactive antibodies. One component showed significant increases in the number and frequencies of unique VH sequences and harbored genes encoding antibodies that were reactive to human HGF and competitive with YYB-101 for HGF binding. Some of the antibodies also reacted to mouse HGF. The selected VH sequences shared 98.3% identity and 98.9% amino acid similarity. It is therefore likely that the antibodies encoded by them all react to the epitope targeted by YYB-101.


Sign in / Sign up

Export Citation Format

Share Document